Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

Perl et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d843a48cb8f39931ae2aa8 — DOI: https://doi.org/10.1056/nejmoa1902688

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial· 2019 · 476 citations
2. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor· 2016 · 283 citations
3. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study· 2017 · 488 citations
4. Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire· 2012 · 138 citations
5. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study· 2011 · 123 citations